Today's biopharmaceutical landscape is seeing a rise in complex next-generation biological molecules. These molecules, with their intricate structures and variations compared to traditional antibody formats, present unique challenges for manufacturers.

This webinar leverages case studies to explore innovative analytical strategies that tackle common hurdles faced during the development of these new molecular formats. Challenges like chain assembly, molecules with multiple mechanisms of action (MoAs), and the presence of diverse post-translational modifications are addressed. Additionally, the webinar focuses on meeting Biologics License Application (BLA) requirements and ensuring thorough process characterization.

You may also be interested in:
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center